New combo therapy boosts blood counts in severe anemia patients
NCT ID NCT04328727
First seen Jan 22, 2026 · Last updated May 23, 2026 · Updated 23 times
Summary
This study tested whether adding eltrombopag to standard treatment (anti-thymocyte globulin and cyclosporine) helps East-Asian patients with severe aplastic anemia, a condition where the bone marrow fails to produce enough blood cells. 36 adults and children received the combination therapy. The main goal was to see how many achieved normal blood cell counts by 26 weeks. The approach aims to control the disease, not cure it, as patients may need ongoing medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA (SAA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450052, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330006, China
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Tianjin, 300020, China
-
Novartis Investigative Site
Tianjin, 300052, China
-
Novartis Investigative Site
Nagoya, Aichi-ken, 466 8560, Japan
-
Novartis Investigative Site
Fukuoka, Fukuoka, 812-8582, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104 8560, Japan
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 06351, South Korea
-
Novartis Investigative Site
Kaohsiung City, 83301, Taiwan
Conditions
Explore the condition pages connected to this study.